Seeking Alpha

A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference...

A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference today: Seeing solid H1 sales growth in all major businesses; Anticipates US/EU filing for Odanacatib in H113, Tredaptive U.S. filing should come in H113 as well; Januvia showing solid sales growth, YTD June sales were $2.8B; Singulair's U.S. patent expired in August, the company has seen an 87% decline in prescriptions within just a few weeks. (Audio)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs